Increased Risk NAION Label Change: Ozempic, Zepbound, Etc. | FDA 2026

What you need to know: An increased risk NAION label change ordered by the FDA in November applies to Ozempic, Wegovy, Rybelsus, Zepbound, Mounjaro, and other medications in GLP-1 RA drug class.

---

The Prescribing Information documents, or drug labels, for all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) will add information about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) pursuant to an FDA-issued Drug Safety Communication on November 9, 2026. This increased-risk NAION label change applies to Ozempic, Zepbound, and other medications in the GLP-1 RA class of drugs.

From that November 2026 FDA document, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition“, regarding the significance of this increased risk NAION label change:

Patients and caregivers should be aware of a potential increased risk of NAION, a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss, with GLP-1 RA use.

Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking; blurred or missing portions of vision (visual defects such as blind spots or tunnel vision); distortion of colors; and reduced central sharpness (e.g., blurry or hazy spots). Patients should contact their health care professional right away if they have any of these symptoms.

If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it.

Before and after this increased risk NAION label change, we are investigating possible drug injury lawsuits for people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus — all of which are semaglutide-containing drugs — as well as people who were using Zepbound or Mounjaro — both of which are tirzepatide-containing drugs.

Coincidentally, our last Drug Injury Watch article on this NAION side-effect drug safety issue was published on October 16, 2026: “Vision Loss Associated With Ozempic, Mounjaro, And Other GLP-1 Drugs – People With Vision Loss Want Warnings Even If Risk Of NAION Eye Injury Is Low“.

For people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus, as well as people diagnosed with NAION while using Zepbound or Mounjaro, we provide possible drug injury lawsuit evaluations that are free, confidential, and without any obligation (that is, no strings attached):

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

Two other ways to get an evaluation of a possible NAION drug injury lawsuit are to email lawyer Tom Lamb at TJL@LambLawOffice.com or call our office at 910-256-2971.

Of course, we are looking to see the legal ramifications of this increased risk NAION label change ordered by the FDA in November 2026 for those drug injury lawsuits already filed for people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus, as well as Zepbound or Mounjaro.

And to be clear, we remain interested in investigating new cases for people diagnosed with NAION while using Ozempic, Zepbound, etc. after this November 2026 increased risk NAION label change.